An interventional study of Group Medical Visits in Mental Health Care, Anxiety and Depression and Pilot Study, sponsored by University of Manitoba. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University of Manitoba · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Depression by University of Manitoba — 6 open to participants now, 7 under way, none of them phase 3. Depression · University of Manitoba.
Among the 23 studies in Depression by University of Manitoba, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, and was the 18th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →6 of the 23 studies in Depression by University of Manitoba are open now, in 1 country. Recruiting first, the newest first:
University of Manitoba · Sites in Canada
Ages 55+ · Healthy volunteers
University of Manitoba · Sites in Canada
Ages 18+
University of Manitoba · Sites in Canada
Ages 6–24
University of Manitoba · Sites in Canada
Ages 18+
University of Manitoba · Sites in Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 56 across the 22 interventional studies, 160 across the 1 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
3 of the studies in Depression by University of Manitoba that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06651801University of ManitobaFeasibility and Acceptability of Group Medical Visits for Anxiety and Depression | 2026-12 |
| NCT07837791University of ManitobaImplementing BEAM: A Scalable Digital Mental Health Program, for Families of Children Referred to Neurodevelopmental Services | 2027-05 |
| NCT07026838University of ManitobaAdvancing Family Wellbeing Through a Massive Open Online Intervention: The LightBEAM Program | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Depression by University of Manitoba, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the feasibility and acceptability of the intervention, Group Medical Visits (GMVs), for patients with depression and anxiety. It also aims to get some initial information on the effectiveness of GMVs on reducing depression and anxiety scores, which will help inform power calculations for a future larger randomized controlled trial (RCT). The main question it aims to answer is:
This study consists of a pilot RCT with an intervention and control arm. At enrollment, participants will be randomized to the intervention group, 6 months of GMVs, or to the control group, which consists of "standard client services". For the GMV group, participants will engage in a biweekly virtual group that is similar to a standard psychiatric follow-up. Participants in the control group will receive standard care after a psychiatric assessment, which includes follow-up with their primary care provider (family physician or nurse practitioner), individual psychiatric care if suggested by the psychiatrist who did their psychiatric assessment, and/or a referral to publicly funded therapy groups if interested.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 14, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will follow-up with their primary care provider (family physician or nurse practitioner).
Behavioral: Group Medical Visits
Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
Client Satisfaction Questionnaire-4 Scale (CSQ-4)
Includes 4 items that measure client satisfaction. Items are rated on a 4-point scale, with total score ranging from 4 to 16. A higher score indicates higher satisfaction.
Time frame: Month 3 and month 6 of intervention
Recruitment and Retention Rate
The investigators will examine the rates of how many participants sign up and are enrolled in the program, along with the drop-out rate throughout the program.
Time frame: Baseline, during the intervention, through study completion (estimation 9 months)
Primary Care Provider Satisfaction with Psychiatric Care
The investigators will conduct a telephone survey with the primary care providers (PCPs) of the participants who were randomized to the intervention group. The survey will assess how satisfied the PCPs are with the care that their patient received during the trial. The survey consists of one question assessing overall satisfaction, rated on a 5-item scale from "Very Satisfied" to "Very Dissatisfied", two open ended questions assessing which aspects of care the PCPs were satisfied and not satisfied with, and 5 questions assessing whether they would refer other patients to the program, what benefits were there of having their patient in the program, and what aspects of the program could be improved.
Time frame: Month 6 of intervention
Patient Health Questionnaire-9 (PHQ-9)
Includes 9 items assessing depressive symptom severity. Total score ranges from 0 to 20, with a higher score indicating higher symptom severity.
Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
General Anxiety Disorder-7 (GAD-7)
Includes 7 items assessing anxiety symptom severity. Total score ranges from 0 to 21, with a higher score indicating higher symptom severity.
Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
Recovery Assessment Scale 24 (RAS24)
Includes 24 items assessing personal recovery. Total score ranges from 24 to 120, with higher scores indicating higher levels of recovery.
Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
Mental Health Quality of Life Questionnaire (MHQoL)
Consists of 7 domains with 4 items assessing each. Total score ranges from 0 to 21, with higher scores indicating better quality of life.
Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Nov 2024 → Apr 2025, primary completion Jun 2025 → Dec 2026 and completion Jul 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.